Microgravity during space travel induces significant regulatory changes in the body, posing health risks for astronauts, including alterations in cell morphology and cytoskeletal integrity. The Small Ubiquitin-like Modifier (SUMO) is crucial for cellular adaptation, regulating DNA repair, cytoskeletal dynamics, cell division, and protein turnover-all processes affected by microgravity. To determine the extent to which SUMO mediates the cellular response to microgravity stress, Saccharomyces...

Currently, the use of scintillation crystals connected via optical fiber to a luminescence spectrometer (so-called fiber-optic dosimeters) offers a promising approach for real-time dosimetric measurements during brachytherapy treatments with γ-ray sources. This study aims to evaluate the applicability of fiber-optic dosimeters for in situ dose measurements during brachytherapy procedures, using Al(2)O(3):C and Al(2)O(3):C,Mg crystals, which have near-tissue density and effective atomic number (ρ...

Mini-LC systems, including Cap-LC, Nano-LC and Chip-LC, offer a sustainable alternative to conventional LC methods thanks to their reduced solvent consumption, enhanced separation efficiency and environmentally friendly operation. Integrating micro-scale sample preparation techniques, such as µ-SPE, IT-SPME, LPME and QuEChERS, with Mini-LC significantly improving analytical sensitivity and selectivity. Mini-LC coupled with mass spectrometry has demonstrated excellent performance in the detection...

Carbon ion radiation therapy (CIRT) is a high-LET radiotherapy, which distinguishes itself from traditional low-LET radiation, such as photons and protons, through its unique physical aspects, biological attributes, and the dramatically increased damage it causes within cellular DNA. Given its distinctive characteristics, it is expected to improve the therapeutic ratio of radiation treatments and enhance treatment outcomes in traditionally radiation-resistant tumor histologies. Despite these...

Background: Epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs) have exhibited efficacy in EGFR-mutant non-small cell lung cancer (NSCLC) patients. However, the response is modest in patients with wild-type (wt)-EGFR, and approximately 30-40% of patients develop TKI resistance. Recently, a role for BRG1 (SMARCA4) in regulating gene expression and its frequent alteration in various cancers, including NSCLC, has been reported. Yet, its specific function in response...